Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,350,000 shares of the company’s stock after selling 205,555 shares during the period. Kymera Therapeutics makes up about 4.6% of Avoro Capital Advisors LLC’s holdings, making the stock its 7th largest holding. Avoro Capital Advisors LLC owned 8.83% of Kymera Therapeutics worth $359,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC lifted its holdings in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after buying an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after buying an additional 491,737 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the period. Finally, Geode Capital Management LLC grew its stake in Kymera Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock valued at $52,075,000 after acquiring an additional 59,347 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 4,895 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the sale, the chief financial officer directly owned 232,588 shares of the company’s stock, valued at approximately $19,839,756.40. This represents a 2.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 4,895 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the sale, the insider owned 117,134 shares of the company’s stock, valued at approximately $9,991,530.20. This represents a 4.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 196,561 shares of company stock valued at $17,097,428. Company insiders own 16.01% of the company’s stock.

Kymera Therapeutics Stock Up 2.0%

Shares of KYMR stock opened at $79.03 on Friday. The business’s fifty day moving average is $79.21 and its 200 day moving average is $68.15. The stock has a market cap of $6.45 billion, a price-to-earnings ratio of -21.48 and a beta of 2.20. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the prior year, the firm earned ($0.88) earnings per share. The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on KYMR shares. Piper Sandler upped their target price on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Barclays boosted their price target on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. Wells Fargo & Company upped their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Bank of America boosted their target price on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.